Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
Date:11/6/2009

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® opthalmic solution on the first day following patent expiration. This strength of ketorolac is therapeutically equivalent to Acular® Ophthalmic Solution, 0.5%, from Allergan, Inc. Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular® opthalmic solution has annual sales of approximately $40 million in the US.

Acular® is a registered trademark of Allergan, Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
2. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
4. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
9. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
10. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016 BioNovus Innovations LLC ... for Advancing Medical Innovation (IAMI) today announced a ... diagnostics and medical devices. An agreement ... rights to license, develop and commercialize medical innovations ... "This partnership represents a significant advance in ...
(Date:5/3/2016)... 3, 2016   BIOTRONIK , a leader ... Food and Drug Administration (FDA) approval of Iperia ... heart failure patients with access to diagnostic magnetic ... remote monitoring with daily automatic transmission and closed ... in response to physiological demands. ...
(Date:5/3/2016)... , May 3, 2016 According ... Size, Share, Development, Growth and Demand Forecast to 2022 ... Field Strength (High Field, Very High Field, Low to ... Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic and ... magnetic resonance imaging (MRI) market was valued at $5,351.7 ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes ... first Team Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and ... Weir and Jason Moeschler, who’ll share pro tips with the injured veterans as they rip ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Benefit Advisors (UBA), the ... the latest addition to its family of Partner Firms. Headquartered in Mount Pleasant, ... human resources, and health care consumerism specialists. , “Partnering with UBA will enable ...
(Date:5/5/2016)... Oregon (PRWEB) , ... May 05, 2016 , ... ... Student American Chiropractic Association (SACA) is slated to host the 2016 National SACA ... for all current SACA national officers and chapter officers to come together and ...
(Date:5/5/2016)... Pittsburgh, PA (PRWEB) , ... May 05, 2016 ... ... risk factors among Pittsburgh-area schoolchildren has found that more than 40 percent of ... Deborah Gentile, MD , Director of Allergy and Asthma Clinical Research in the ...
(Date:5/5/2016)... ... May 05, 2016 , ... In order to increase comfort, ... Amerec, a Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , ... of the app, developed for both smartphones and personal computers perfectly emulates that ...
Breaking Medicine News(10 mins):